Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STROBE: Intranasal Oxytocin in Binge-eating Disorder
NCT05664516Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of TNX-1900 in binge eating disorder (BED), bulimia nervosa (BN), sponsored by Massachusetts General Hospital. Started Mar 2023; status: recruiting.
02
Drugs
TNX-1900
03
Conditions
binge eating disorder (BED)bulimia nervosa (BN)
Beyond the preview
Go deeper on NCT05664516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664516.